Webinar: TARGET VALIDATION: THE KEY TO MORE EFFICIENT DRUG DISCOVERY
Sponsored by: Thomson Reuters
Focused on:
Date: 3th August
Days old: 4935
Time: London 3PM / New York 10AM
What alternatives are there to optimized animal models?
The research and development spend by Pharmaceutical companies has continued to rise in the last decade, and at the same time witnessed fewer new drugs coming to market. Late stage failures are proving to be particularly expensive, so the greatest challenge is to identify these potential failures earlier and cheaper. One key approach is to focus effort on target validation: by delivering fewer but stronger candidates earlier, drug development teams could dramatically reduce late stage attrition.
Please join us for a round table discussion, lead by key opinion leaders from the industry, on how integrating key information sources has the potential to validate targets earlier and lead to accelerated development of novel drug candidates. We will examine data taken from recent trends in drug discovery.
There will be a chance for you to post your own questions to the panel for debate during and at the end of the webinar. Please join us to participate in one of the hottest topics in drug discovery today.
Presented by
Dr Cathy Tralau-Stewart ,
Head and Founder of the Imperial College London Drug Discovery Centre
Cathy is Head and Founder of the Imperial College London Drug Discovery Centre. The Centre focuses on validation of novel therapeutic targets, the identification and optimization of small molecule and biological approaches to these targets and their progression towards clinical proof of concept. The Centre is a 'virtual biotech' within academia enabling translation towards the clinic and manages a portfolio of projects ranging from Malaria to Oncology.
Cathy completed her PhD in Clinical Science (Oncology) at University College London in 1989. She is a pharmacologist with more than 20 years experience of drug discovery within GlaxoSmithKline ranging from target validation, through lead optimisation, candidate characterisation and phase I to IV clinical trials. She has also lead project teams to identify over 20 development compound candidates in a range of therapeutic areas, and to the discovery and development of eleven marketed drugs.
Stuart Farrow,
Director -Respiratory Therapy Area, GlaxoSmithKline
Stuart Farrow is a director in the GlaxoSmithKline respiratory therapy area, and also visiting Professor of Experimental Therapeutics at the University of Manchester, where he currently leads a major discovery research collaboration between the University and GSK. Stuart has more than 20 years of drug discovery experience in the pharmaceutical sector, with a particular focus on inflammation and respiratory disease, and has led numerous drug discovery programmes from initial target identification and validation through to clinical proof of concept. He has more than 50 peer reviewed publications, lectures on target discovery to MSc students at several UK universities and is regularly invited to present on target discovery and validation at international respiratory disease conferences.
Download Slides
Please login to download the slidesKey Learning Objectives
- How can we improve success rates?
- Are optimized animal models the only way to go or are there alternatives?
- What added benefits are realized from the inclusion of molecular information? Can we do target validation in patients?
- Are the lessons of yesterday an indication of success tomorrow?
Audience
- CSO
- Chief Scientist
- Head of R&D
- VP R&D
- Scientific Director
- Director R&D
- Director of Chemistry
- Head of Chemistry
- Head of Medicinal Chemistry
- Head of Drug Discovery Head of Discovery Technologies
- Head of Translational Research
- Group Leader Drug Discovery
- Group Leader Medicinal chemistry Group Leader
- Senior Scientist
- Principal Scientist
- Medicinal Chemist
- Biologist